Microangiopathic hemolytic anemia (MAHA) occurs when red blood cells are physically shredded apart as they squeeze through damaged, clot-filled small blood vessels. It’s not a disease on its own — it’s a red flag that something dangerous is happening systemically, most commonly thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), or severe preeclampsia. Recognizing MAHA quickly is a genuine emergency because untreated TTP, for example, carries a mortality rate exceeding 90%.
This guide covers the full arc — from the molecular mechanisms that destroy red blood cells, to the lab findings that clinch the diagnosis, to the management strategies that save lives. Whether you’re a medical student, resident, or clinician refreshing your knowledge, this is the practical walkthrough you need.
What Exactly Happens in MAHA? The Core Mechanism
The unifying pathology behind MAHA is thrombotic microangiopathy (TMA) — endothelial injury in small vessels triggers the deposition of fibrin strands and platelet-rich thrombi throughout the microvasculature. Think of these fibrin strands as razor wires strung across a narrow hallway. Red blood cells are forced through at high pressure and get sliced into fragments called schistocytes.
This mechanical destruction is classified as intravascular hemolysis. The consequences cascade quickly: free hemoglobin spills into plasma, haptoglobin is consumed, LDH skyrockets, and indirect bilirubin rises. Simultaneously, platelets are consumed in the microthrombi, causing thrombocytopenia — sometimes severe enough to cause bleeding.
Major Causes of MAHA
The differential diagnosis for MAHA is broad, but a handful of conditions account for the vast majority of cases. Distinguishing between them is critical because their treatments are completely different.
| Condition | Key Mechanism | Distinguishing Feature |
|---|---|---|
| TTP | ADAMTS13 deficiency (<10% activity) → uncleaved ultra-large VWF multimers → platelet aggregation | Severe thrombocytopenia, neurological symptoms, ADAMTS13 <10% |
| Typical HUS (STEC-HUS) | Shiga toxin from E. coli O157:H7 damages glomerular endothelium | Bloody diarrhea prodrome, predominant renal failure, children <5 years |
| Atypical HUS (aHUS) | Uncontrolled complement activation (mutations in Factor H, Factor I, C3, etc.) | No diarrhea, relapsing course, low C3, complement gene mutations |
| HELLP Syndrome | Placental-mediated endothelial dysfunction | Pregnancy (usually 3rd trimester), elevated AST/ALT, RUQ pain |
| DIC | Systemic coagulation activation consuming clotting factors and platelets | Prolonged PT/INR, low fibrinogen (<150 mg/dL), elevated D-dimer |
| Malignant Hypertension | Shear stress from extreme BP damages endothelium | BP >180/120 with end-organ damage |
| Drug-induced TMA | Direct endothelial toxicity (e.g., cyclosporine, gemcitabine, quinine) | Temporal relationship with offending drug |
Clinical Presentation: What You’ll Actually See
Patients with MAHA typically present with fatigue, pallor, and dyspnea from anemia — but these symptoms alone won’t point you toward MAHA. The clues come from the combination of findings and the clinical context.
In TTP, the classic teaching is a pentad: MAHA, thrombocytopenia, neurological changes, renal dysfunction, and fever. In reality, the full pentad appears in fewer than 5% of cases at presentation. Most patients show just MAHA plus thrombocytopenia, and waiting for the full pentad is a dangerous mistake — treatment delays increase mortality dramatically.
In HUS, renal failure dominates the picture. Children typically present after several days of bloody diarrhea, then develop oliguria, edema, and hypertension. In aHUS, the onset is often more insidious, without a diarrheal trigger.
Diagnostic Workup: The Labs That Matter
When you suspect MAHA, the initial workup should be ordered urgently — ideally within the first hour of suspicion.
Core Lab Panel
- Peripheral blood smear: Look for ≥2 schistocytes per high-power field (some labs use >1% of RBCs). This is the single most important test.
- CBC: Hemoglobin often 6–9 g/dL; platelet count frequently <30,000/μL in TTP
- LDH: Markedly elevated, often >600 U/L (sometimes >2,000 U/L in TTP)
- Haptoglobin: Undetectable (<10 mg/dL) — the most sensitive marker of intravascular hemolysis
- Indirect bilirubin: Elevated (usually 2–5 mg/dL)
- Direct Coombs test: Negative — this distinguishes MAHA from autoimmune hemolytic anemia
- Reticulocyte count: Elevated, reflecting marrow compensation
Tests to Differentiate the Cause
- ADAMTS13 activity: <10% is diagnostic of TTP. Send this BEFORE starting plasma exchange, but don’t wait for results to treat.
- Coagulation studies (PT, PTT, fibrinogen, D-dimer): Normal in TTP/HUS. Abnormal values (prolonged PT, low fibrinogen) point toward DIC.
- Creatinine and urinalysis: Disproportionate renal failure suggests HUS over TTP
- Complement levels (C3, C4) and genetic testing: For suspected aHUS
- Stool culture / Shiga toxin assay: If diarrheal HUS is suspected
- Pregnancy test and liver enzymes: To rule out HELLP
Management: Treat the Cause, Not Just the Anemia
MAHA management is entirely driven by the underlying diagnosis. There is no “one-size-fits-all” approach, and choosing the wrong treatment can be fatal.
TTP: Plasma Exchange Is Life-Saving
Therapeutic plasma exchange (TPE) is the cornerstone of TTP treatment and should be initiated within hours of clinical suspicion — even before ADAMTS13 results return. TPE removes autoantibodies against ADAMTS13 and replaces the deficient enzyme. Before plasma exchange became standard, TTP mortality was >90%; with TPE, survival exceeds 80–90%.
Caplacizumab, an anti-VWF nanobody, is now used alongside TPE and immunosuppression. The HERCULES trial showed it reduced time to platelet normalization and decreased the rate of TTP-related death or recurrence by 74%. Corticosteroids and rituximab are added for immunosuppression.
Critical point: Do NOT transfuse platelets in TTP unless there is life-threatening bleeding. Platelet transfusions can fuel microthrombi and precipitate strokes or organ failure.
HUS: Supportive Care vs. Complement Blockade
Typical (Shiga toxin-associated) HUS is managed with supportive care: IV fluids, blood pressure control, dialysis if needed. Antibiotics are generally avoided in STEC infection — they may increase Shiga toxin release and worsen outcomes. Most children recover renal function within 2–3 weeks.
Atypical HUS is treated with eculizumab (Soliris) or ravulizumab (Ultomiris), terminal complement inhibitors that block C5 cleavage. These drugs have transformed aHUS from a condition with ~50% progression to end-stage renal disease into one with >80% hematologic remission rates.
Other Causes
- HELLP syndrome: Delivery of the baby is definitive treatment
- DIC: Treat the underlying trigger (sepsis, malignancy); supportive transfusion of FFP, cryoprecipitate, platelets
- Malignant hypertension: Aggressive IV antihypertensive therapy (nicardipine, nitroprusside)
- Drug-induced TMA: Immediate discontinuation of the offending agent
When to See a Doctor
MAHA is never something to “watch and wait.” If you or a family member has unexplained anemia with bruising, confusion, dark or reduced urine output, or bloody diarrhea followed by swelling and fatigue, seek emergency care immediately.
For clinicians: any patient with the triad of anemia + thrombocytopenia + elevated LDH and a negative Coombs test should be evaluated for MAHA on an emergent basis. Send ADAMTS13, order a blood smear, and consult hematology — don’t wait for all results before acting.
Frequently Asked Questions
What is the difference between MAHA and other types of hemolytic anemia?
MAHA is specifically mechanical destruction of red blood cells by abnormal microvasculature. Other hemolytic anemias involve immune-mediated destruction (autoimmune hemolytic anemia, positive Coombs test), membrane defects (hereditary spherocytosis), or enzyme deficiencies (G6PD deficiency). The hallmark of MAHA is schistocytes on the blood smear with a negative Coombs test.
How many schistocytes confirm MAHA?
The International Council for Standardization in Haematology (ICSH) defines a clinically significant schistocyte count as >1% of red blood cells on a peripheral smear. In practice, most hematologists consider ≥2 schistocytes per high-power field in the right clinical context to be highly suggestive. A single schistocyte on a smear is nonspecific.
Can MAHA be cured?
It depends entirely on the cause. STEC-HUS in children typically resolves completely. TTP can be put into remission with plasma exchange and immunosuppression, though relapse occurs in 20–50% of cases. aHUS may require long-term or indefinite complement inhibitor therapy. Drug-induced TMA often resolves after stopping the offending medication.
Why shouldn’t you transfuse platelets in TTP?
In TTP, the problem is excessive platelet aggregation in small vessels. Adding more platelets provides more fuel for microthrombus formation, potentially triggering strokes, myocardial infarctions, or multi-organ failure. Platelet transfusion is reserved only for active life-threatening hemorrhage in TTP patients.
What is the PLASMIC score?
The PLASMIC score is a validated clinical prediction tool that estimates the likelihood of severe ADAMTS13 deficiency (i.e., TTP). It incorporates platelet count, hemolysis markers, MCV, INR, creatinine, and the absence of active cancer or organ transplant. A score of ≥6 (out of 7) has a positive predictive value of approximately 72% for ADAMTS13 <10%. It helps guide the urgency of initiating plasma exchange while awaiting ADAMTS13 results.
